Marshall Wace
MRNA icon

Marshall Wace’s Moderna MRNA Stock Holding History

Marshall Wace’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7K Sell
163
-133,652
-100% -$6.91M ﹤0.01% 3071
2026
Q1 		$6.8M Buy
133,815
+14,374
+12% +$671K 0.01% 1153
2025
Q4 		$3.52M Sell
119,441
-145,932
-55% -$3.96M ﹤0.01% 1314
2025
Q3 		$6.85M Buy
+265,373
New +$7.4M 0.01% 1069
2024
Q3 		– Sell
-35,200
Closed -$4.18M – 2800
2024
Q2 		$4.18M Buy
35,200
+26,300
+296% +$3.33M 0.01% 1076
2024
Q1 		$948K Sell
8,900
-68,000
-88% -$6.85M ﹤0.01% 1678
2023
Q4 		$7.65M Buy
76,900
+71,142
+1,236% +$5.98M 0.01% 764
2023
Q3 		$595K Sell
5,758
-3,242
-36% -$362K ﹤0.01% 1665
2023
Q2 		$1.09M Buy
9,000
+6,839
+316% +$912K ﹤0.01% 1676
2023
Q1 		$332K Sell
2,161
-287,481
-99% -$47.4M ﹤0.01% 2260
2022
Q4 		$52M Sell
289,642
-380,659
-57% -$62.2M 0.12% 192
2022
Q3 		$79.3M Buy
670,301
+44,546
+7% +$6.76M 0.17% 117
2022
Q2 		$89.4M Sell
625,755
-183,380
-23% -$26.2M 0.18% 116
2022
Q1 		$139M Buy
809,135
+763,285
+1,665% +$129M 0.26% 71
2021
Q4 		$11.6M Buy
45,850
+42,828
+1,417% +$12.5M 0.02% 761
2021
Q3 		$1.16M Buy
3,022
+338
+13% +$125K ﹤0.01% 1929
2021
Q2 		$631K Sell
2,684
-67,483
-96% -$12.1M ﹤0.01% 2026
2021
Q1 		$9.19M Sell
70,167
-182,117
-72% -$26.4M 0.04% 498
2020
Q4 		$26.4M Buy
+252,284
New +$25.5M 0.14% 143
2020
Q3 		– Sell
-34,979
Closed -$2.25M – 1803
2020
Q2 		$2.25M Buy
+34,979
New +$1.92M 0.02% 747
2019
Q3 		– Sell
-114,512
Closed -$1.68M – 1838
2019
Q2 		$1.68M Buy
+114,512
New +$2.46M 0.01% 818

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Marshall Wace's MRNA Position: Q2 2026 in Review

Marshall Wace reduced its Moderna (MRNA) stake by 100% in Q2 2026, selling an estimated $6.91M and leaving 163 shares worth $11.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3071.

Marshall Wace first reported a position in MRNA in Q2 2019 and has held it in 21 quarters since. The position peaked at $139M in Q1 2022. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Marshall Wace held 163 shares of Moderna worth $11.7K as of Q2 2026.
  • Marshall Wace sold 133,652 Moderna shares in Q2 2026, an estimated $6.91M.
  • Moderna made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #3071 holding.
  • Marshall Wace first reported a position in Moderna in Q2 2019 and has held it in 21 quarters since.
  • Marshall Wace's Moderna position peaked at $139M in Q1 2022.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.